E-viri
PDF
Recenzirano
Odprti dostop
-
Madhi, Shabir A; Baillie, Vicky; Cutland, Clare L; Voysey, Merryn; Koen, Anthonet L; Fairlie, Lee; Padayachee, Sherman D; Dheda, Keertan; Barnabas, Shaun L; Bhorat, Qasim E; Briner, Carmen; Kwatra, Gaurav; Ahmed, Khatija; Aley, Parvinder; Bhikha, Sutika; Bhiman, Jinal N; Bhorat, As’ad E; du Plessis, Jeanine; Esmail, Aliasgar; Groenewald, Marisa; Horne, Elizea; Hwa, Shi-Hsia; Jose, Aylin; Lambe, Teresa; Laubscher, Matt; Malahleha, Mookho; Masenya, Masebole; Masilela, Mduduzi; McKenzie, Shakeel; Molapo, Kgaogelo; Moultrie, Andrew; Oelofse, Suzette; Patel, Faeezah; Pillay, Sureshnee; Rhead, Sarah; Rodel, Hylton; Rossouw, Lindie; Taoushanis, Carol; Tegally, Houriiyah; Thombrayil, Asha; van Eck, Samuel; Wibmer, Constantinos K; Durham, Nicholas M; Kelly, Elizabeth J; Villafana, Tonya L; Gilbert, Sarah; Pollard, Andrew J; de Oliveira, Tulio; Moore, Penny L; Sigal, Alex; Izu, Alane
The New England journal of medicine, 05/2021, Letnik: 384, Številka: 20Journal Article
A double-blind randomized trial in South Africa documented poor efficacy of two doses of the ChAdOx1 nCoV-19 vaccine against the B.1.351 variant of SARS-CoV-2 that emerged in South Africa. Infections occurred in 3.2% of placebo recipients and in 2.5% of vaccine recipients. Thirty-nine of the 42 virus isolates were the B.1.351 variant. None of the cases led to hospitalization or death.
